Kymera Therapeutics, Inc.
Financials
Valuation Metrics
Kymera Therapeutics, Inc.'s Market Cap is $10.42B. At end of 2025 it was $6.57B. Ranked #912 of 3,116 in US market (top 29%), #287 of 1,472 on NASDAQ (top 19%), #43 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 16%) by Market Cap.
Investment Metrics(as of 2026-10-30)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $10.42B | US#912/3,116 Sec#43/265 |
| Revenue | $105M | US#2,664/3,116 Sec#123/265 |
| Net Income | $-300M | US—/3,116 Sec—/265 |
| Total Assets | $1.65B | US#2,200/3,116 Sec#64/265 |
| Net Assets | $1.51B | US#1,462/3,116 Sec#45/265 |
| Employees | 273 | US#2,424/3,116 Sec#115/265 |
| Value | ||
| P/B | 6.90x | US#2,404/3,116 Sec#168/265 |
| P/S | 99.27x | US#2,942/3,116 Sec#180/265 |
| FCF Yield | -2.28% | US—/3,116 Sec—/265 |
| Profitability | ||
| ROE | -19.85% | US#2,472/3,116 Sec#100/265 |
| ROA | -18.21% | US#2,769/3,116 Sec#127/265 |
| Op. Margin | -333.73% | US#2,764/3,116 Sec#145/265 |
| Revenue Growth | 135.63% | US#72/3,116 Sec#26/265 |
| Financial Health | ||
| Debt Ratio | 9.27% | US#99/3,116 Sec#47/265 |
| Total Debt | $82M | US#2,479/3,116 Sec#130/265 |
| FCF | $-238M | US#2,813/3,116 Sec#223/265 |
| Cash | $124M | US#2,069/3,116 Sec#153/265 |
| Current Ratio | 9.83x | US#252/3,116 Sec#79/265 |
| Performance | ||
| 1Y Return | 106.10% | US#141/3,116 Sec#34/265 |
| 1M Return | 13.27% | US#653/3,116 Sec#41/265 |
| From 52W High | -2.63% | US#530/3,116 Sec#37/265 |
| 1Y MDD | -27.74% | US#1,142/3,116 Sec#53/265 |
| Trading | ||
| Volume | 1,542,550 shares | US#1,460/3,116 Sec#145/265 |
| Trading Value | $191M | US#757/3,116 Sec#40/265 |
| Per Share | ||
| EPS | $-3.64 | US—/3,116 Sec—/265 |
| BPS | $18.35 | US#1,326/3,116 Sec#33/265 |
Company Info
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.